0.197
02.80 (14.23%)
As of Mar 06, 2024
TRACON PHARMACEUTICALS, INC. [TCON]
As of Mar 05, 2024 | Source: Annual Report to the SEC
Company Overview
Tracon Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer and utilizing our cost efficient, contract research organization (CRO) independent product development platform to partner with other life science companies to develop and commercialize innovative products in the United States.
| Country | United States |
| Headquarters | San Diego, California |
| Phone Number | 858-550-0780 |
| Industry | Chemicals And Allied Products |
| Employees | 17 |
| CEO | Charles P. Theuer, M.D., Ph.D. |
| Website | www.traconpharma.com |
Key fundamental financials loss of $6.29 million Revenue of $9 million Current Reporting Revenue Net Income Profit/Loss Jun 2023 $9 million $6.29 million loss Sep 2022 $0 $6,435 loss Tracon Pharmaceut...
Tracon Pharmaceuticals, Inc. [TCON] has posted annual profit of $0 million for the year ended Dec 31,2022. The company based in California(CA)reported a fellin revenue to $0 milion for the year when c...
Tracon Pharmaceuticals, Inc. [TCON] As of Aug 08, 2017| Source: Quarterly Report to the SEC We are a biopharmaceutical company focused on the development and commercialization of novel targeted therap...
Tracon Pharmaceuticals, Inc. [TCON] As of Nov 07, 2017| Source: Quarterly Report to the SEC We are a biopharmaceutical company focused on the development and commercialization of novel targeted therap...
Tracon Pharmaceuticals, Inc. [TCON] As of May 10, 2017| Source: Quarterly Report to the SEC We are a biopharmaceutical company focused on the development and commercialization of novel targeted therap...
Financial Overview
| Revenue | 12,045 K |
| Operating Revenue | -9,273 K |
| Profits | -3,588 K |
| Net Cash | -8,863 K |
Management Effectiveness
| Return on Equity | 0.44% |
| Return on Assets | -0.04% |
| Turnover Ratio | 0 K |
| EBIT | -9,273 K |
Profit Ratios
| Operating Margin | -76.99% |
| Profit as % of Assets | -0.02% |
| Profit as % of Stockholder Equity | 0.44% |
Balance Sheet and Cash Flow Measures
| Total Assets | 10,105,000 W |
| Total Liabilities | 10,914,000 W |
| Operating Cash Flow | 3,676 K |
| Investing Cash Flow | 000 K |
| Financing Cash Flow | -12,539 K |